Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.
This report studies the market from 2005 to 2020 covering eleven major drugs (off-patent and pipeline) for lung cancer treatment. Growing lung cancer population is an impetus for the growth of the market. This market is expected to grow at a CAGR of 13.5% from 2015 to 2020. The U.S. was the major contributor to this market; accounting for 67% of the total sales of lung cancer drugs in 2010; whereas Avastin was the major drug accounting for 27.1% of the total sales of lung cancer drugs in 2010.
This report studies the market from 2005 to 2020 covering eleven major drugs (off-patent and pipeline) for lung cancer treatment. Growing lung cancer population is an impetus for the growth of the market. This market is expected to grow at a CAGR of 13.5% from 2015 to 2020. The U.S. was the major contributor to this market; accounting for 67% of the total sales of lung cancer drugs in 2010; whereas Avastin was the major drug accounting for 27.1% of the total sales of lung cancer drugs in 2010.
Buy Now: G7 lung cacner drugs market
The report studies eight off-patent and patented drugs including Navelbine, Hycamtin, Taxotere, Gemzar, Alimta, Iressa, Avastin, and Tarceva. Currently, there are about five major drugs in pipeline for lung cancer; which are expecting a market launch by 2013-2014. Mage-A3 Antigen by GlaxoSmithKline commenced its phase III trial in 2007 and the completion is expected by 2022 involving 2,270 patients.
The report studies eight off-patent and patented drugs including Navelbine, Hycamtin, Taxotere, Gemzar, Alimta, Iressa, Avastin, and Tarceva. Currently, there are about five major drugs in pipeline for lung cancer; which are expecting a market launch by 2013-2014. Mage-A3 Antigen by GlaxoSmithKline commenced its phase III trial in 2007 and the completion is expected by 2022 involving 2,270 patients.
Ø Xalkori has been launched in the market by Pfizer Inc. (U.S.) on receiving an accelerated approval from the FDA in August 2011. The drug is expected to be priced at $9,600 a month or $115,000 for patients who take them annually.
Ø Players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2006 to September 2011.
Ø New product launches/approvals form a major growth strategy in the Lung Cancer Drugs Market in G7 Countries; accounting for 45% share in this market between January 2006 and September 2011, followed by pipeline drugs with a 23% share in the market and agreements and collaborations with 18% share.
Ø Lung cancer drugs have a robust pipeline with five drugs; of which Xalkori has received a fast track approval in its late phase II. The drug (Xalkori) has been launched in the market in August 2011 in the U.S. and is under review by the European Medical Agency.
Ø Roche, AstraZeneca, Eli Lilly and Company, Sanofi-Aventis, Pfizer, and GlaxoSmithKline rule the present market for lung cancer drugs; whereas Agennix AG & Pfizer are expected to capture about 50% of the market by 2020.
Scope of the report
The Lung Cancer Drugs Market research report evaluates the drugs market of lung cancer in G7 countries with respect to the current and pipeline drugs. The report analyzes geography; forecasting revenue, and trends in each of the following submarkets:
Chemotherapy
Navelbine
Hycamtin
Taxotere
Alimta
Gemzar
Targeted therapies
Avastin
Tarceva
Iressa
Pipeline drugs
ARQ 197
Xalkori
afatinib
dacomitinib
talactoferrin
The geographies covered under the report are
North America
U.S.
Canada
Europe
U.K.
Germany
Italy
France
Spain
Each section provides market data, market drivers, trends and opportunities, key players, and competitive outlook. This report also provides market tables for covering the sub-segments and micro-markets. Additionally, it makes ways for company profiles that cover all the sub-segments. The report has been made by keeping past trends, current happenings, and future forecasts in consideration.
Related Market Research Reports:
About Us:
ReportsnReports.com is an online market research library of 135,000+ reports and in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. Visit http://www.reportsnreports.com/ for more details.
Contact:
Priyank Tiwari
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-391-5441
sales@reportsandreports.com
Visit our Market Research Blog @ http://www.reportsnreportsblog.com/
Connect with us on:
Twitter @ http://www.twitter.com/marketsreports
No comments:
Post a Comment